LU91399I2 - "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard - Google Patents
"La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-SilgardInfo
- Publication number
- LU91399I2 LU91399I2 LU91399C LU91399C LU91399I2 LU 91399 I2 LU91399 I2 LU 91399I2 LU 91399 C LU91399 C LU 91399C LU 91399 C LU91399 C LU 91399C LU 91399 I2 LU91399 I2 LU 91399I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- recombinant
- protein
- silgard
- gardasil
- human papillomavirus
- Prior art date
Links
- 241000341655 Human papillomavirus type 16 Species 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 101710121996 Hexon protein p72 Proteins 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 208000003154 papilloma Diseases 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90310992A | 1992-06-25 | 1992-06-25 | |
PCT/US1993/006109 WO1994000152A1 (fr) | 1992-06-25 | 1993-06-24 | Vaccin contre le papillomavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91399I2 true LU91399I2 (fr) | 2008-02-14 |
Family
ID=25416951
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91395C LU91395I2 (fr) | 1992-06-25 | 2005-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix |
LU91396C LU91396I2 (fr) | 1992-06-25 | 2007-12-14 | "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard |
LU91397C LU91397I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard |
LU91400C LU91400I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard |
LU91393C LU91393I2 (fr) | 1992-06-25 | 2007-12-14 | "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix |
LU91399C LU91399I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard |
LU91398C LU91398I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard |
LU91394C LU91394I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91395C LU91395I2 (fr) | 1992-06-25 | 2005-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix |
LU91396C LU91396I2 (fr) | 1992-06-25 | 2007-12-14 | "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard |
LU91397C LU91397I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard |
LU91400C LU91400I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard |
LU91393C LU91393I2 (fr) | 1992-06-25 | 2007-12-14 | "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91398C LU91398I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard |
LU91394C LU91394I2 (fr) | 1992-06-25 | 2007-12-14 | "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix |
Country Status (12)
Country | Link |
---|---|
US (2) | US20020068326A1 (fr) |
EP (2) | EP0647140B1 (fr) |
AT (1) | ATE380871T1 (fr) |
AU (1) | AU697743C (fr) |
DE (9) | DE122007000094I1 (fr) |
DK (1) | DK0647140T3 (fr) |
ES (1) | ES2294778T3 (fr) |
FR (1) | FR07C0073I2 (fr) |
LU (8) | LU91395I2 (fr) |
NL (8) | NL300319I1 (fr) |
PT (1) | PT647140E (fr) |
WO (1) | WO1994000152A1 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1359156B1 (fr) | 1991-07-19 | 2007-03-07 | University of Queensland | Vaccin contre le Papillomavirus Humain (Type 18) |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
US8062642B1 (en) | 1993-03-09 | 2011-11-22 | University Of Rochester | Production of papillomavirus capsid protein and virus-like particles |
DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
HUT76354A (en) * | 1994-05-16 | 1997-08-28 | Merck & Co Inc | Papillomavirus vaccines |
AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
AU683564B2 (en) * | 1994-05-17 | 1997-11-13 | University Of Queensland, The | Recombinant papilloma virus L1 |
RU2177999C2 (ru) * | 1994-09-22 | 2002-01-10 | Мерк Энд Ко., Инк. | Экспрессирующий вектор (варианты) |
US6066324A (en) | 1994-10-07 | 2000-05-23 | Loyola University Of Chicago | Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles |
US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
CA2295316C (fr) * | 1997-07-03 | 2007-06-26 | University Of Colorado, University Technology Corporation | Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques |
US6228368B1 (en) | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
CA2229955C (fr) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
US6242176B1 (en) | 1998-07-13 | 2001-06-05 | Loyola University Of Chicago | Papillomavirus cellular receptor |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
CN101926993B (zh) * | 1998-10-16 | 2013-12-04 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂系统及疫苗 |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
US7247433B2 (en) | 2001-08-13 | 2007-07-24 | University Of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
EP2486938B1 (fr) | 2006-09-26 | 2018-05-09 | Infectious Disease Research Institute | Composition de vaccin contenant un adjuvant synthétique |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
MX362698B (es) | 2007-03-02 | 2019-02-01 | Glaxosmithkline Biologicals Sa | Metodo novedoso y composiciones. |
ES2565846T3 (es) | 2008-05-26 | 2016-04-07 | Cadila Healthcare Limited | Vacuna combinada contra el sarampión-papiloma humano |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
WO2010112533A1 (fr) * | 2009-04-03 | 2010-10-07 | Deutsches Krebsforschungszentrum | Augmentation de la production de particules analogues au papillomavirus avec un système d'expression de baculovirus modifié |
CA2764374C (fr) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Adjuvants lipidiques synthetiques a base de glucopyranosyle |
WO2011026111A1 (fr) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale |
US9322827B2 (en) | 2010-04-08 | 2016-04-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | B-cell antigen presenting cell assay |
JP6054942B2 (ja) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
DK2811981T3 (da) | 2012-02-07 | 2019-06-11 | Infectious Disease Res Inst | Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf |
JP6619648B2 (ja) | 2012-05-16 | 2019-12-11 | イミューン デザイン コーポレイション | Hsv−2のためのワクチン |
CN109134640A (zh) | 2012-10-23 | 2019-01-04 | 爱默蕾大学 | Gm-csf和il-4轭合物、组合物以及与其相关的方法 |
CN105209047B (zh) | 2013-04-18 | 2020-08-18 | 免疫设计股份有限公司 | 用于癌症治疗的gla单一疗法 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
AU2014373928C1 (en) | 2013-12-31 | 2020-12-17 | Access To Advanced Health Institute | Single vial vaccine formulations |
EP3420355A1 (fr) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica GmbH | Procédé d'immobilisation de biomolécules |
IL313085A (en) | 2016-05-16 | 2024-07-01 | Access To Advanced Health Inst | Pegylated liposomes and methods of use |
HUE059605T2 (hu) | 2016-05-16 | 2022-11-28 | Access To Advanced Health Inst | TLR agonista tartalmú készítmény és használati eljárások |
MX2018014399A (es) | 2016-06-01 | 2019-06-06 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento. |
US11141377B2 (en) | 2017-06-15 | 2021-10-12 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
KR20220125149A (ko) | 2019-05-25 | 2022-09-14 | 액세스 투 어드밴스드 헬스 인스티튜트 | 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법 |
WO2022051022A1 (fr) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Arn co-lyophilisé et support lipidique nanostructuré |
WO2024052882A1 (fr) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Composition de vaccin immunogène incorporant une saponine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106626A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
US4455296A (en) * | 1982-02-02 | 1984-06-19 | Board Of Regents, The University Of Texas System | Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
FR2524487B1 (fr) * | 1982-04-05 | 1985-11-22 | Pasteur Institut | Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants |
US4596674A (en) * | 1984-09-11 | 1986-06-24 | Merck & Co., Inc. | Immunogenic HAV peptides |
DE3625257A1 (de) * | 1986-07-23 | 1988-02-04 | Behringwerke Ag | Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika |
NZ223009A (en) * | 1986-12-31 | 1990-06-26 | Nl Rivm Of Thoven | Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens |
EP0320942A3 (fr) * | 1987-12-18 | 1989-10-04 | American Cyanamid Company | Polysaccharides et composés macromoléculaires contenant ces polysaccharides |
KR910016343A (ko) * | 1990-03-20 | 1991-11-05 | 스타인, 부그 | 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프 |
EP1359156B1 (fr) | 1991-07-19 | 2007-03-07 | University of Queensland | Vaccin contre le Papillomavirus Humain (Type 18) |
-
1993
- 1993-06-24 DE DE122007000094C patent/DE122007000094I1/de active Pending
- 1993-06-24 DE DE122007000099C patent/DE122007000099I1/de active Pending
- 1993-06-24 DE DE69334192T patent/DE69334192T2/de not_active Expired - Lifetime
- 1993-06-24 DE DE122007000098C patent/DE122007000098I1/de active Pending
- 1993-06-24 DE DE122007000096C patent/DE122007000096I1/de active Pending
- 1993-06-24 DE DE122007000101C patent/DE122007000101I1/de active Pending
- 1993-06-24 EP EP93916789A patent/EP0647140B1/fr not_active Expired - Lifetime
- 1993-06-24 DE DE122007000095C patent/DE122007000095I1/de active Pending
- 1993-06-24 AT AT93916789T patent/ATE380871T1/de active
- 1993-06-24 PT PT93916789T patent/PT647140E/pt unknown
- 1993-06-24 DE DE122007000097C patent/DE122007000097I1/de active Pending
- 1993-06-24 DK DK93916789T patent/DK0647140T3/da active
- 1993-06-24 EP EP07013259A patent/EP1835029A1/fr not_active Withdrawn
- 1993-06-24 ES ES93916789T patent/ES2294778T3/es not_active Expired - Lifetime
- 1993-06-24 DE DE122007000100C patent/DE122007000100I1/de active Pending
- 1993-06-24 WO PCT/US1993/006109 patent/WO1994000152A1/fr active IP Right Grant
-
1995
- 1995-01-24 AU AU11352/95A patent/AU697743C/en not_active Expired
- 1995-06-07 US US08/473,228 patent/US20020068326A1/en not_active Abandoned
-
1996
- 1996-12-16 US US08/764,926 patent/US8012679B1/en not_active Expired - Fee Related
-
2005
- 2005-12-14 LU LU91395C patent/LU91395I2/fr unknown
-
2007
- 2007-12-14 LU LU91396C patent/LU91396I2/fr unknown
- 2007-12-14 NL NL300319C patent/NL300319I1/nl unknown
- 2007-12-14 LU LU91397C patent/LU91397I2/fr unknown
- 2007-12-14 NL NL300315C patent/NL300315I2/nl unknown
- 2007-12-14 LU LU91400C patent/LU91400I2/fr unknown
- 2007-12-14 LU LU91393C patent/LU91393I2/fr unknown
- 2007-12-14 LU LU91399C patent/LU91399I2/fr unknown
- 2007-12-14 NL NL300322C patent/NL300322I1/nl unknown
- 2007-12-14 NL NL300317C patent/NL300317I1/nl unknown
- 2007-12-14 NL NL300320C patent/NL300320I1/nl unknown
- 2007-12-14 NL NL300318C patent/NL300318I2/nl unknown
- 2007-12-14 LU LU91398C patent/LU91398I2/fr unknown
- 2007-12-14 LU LU91394C patent/LU91394I2/fr unknown
- 2007-12-14 NL NL300316C patent/NL300316I1/nl unknown
- 2007-12-14 NL NL300321C patent/NL300321I1/nl unknown
- 2007-12-21 FR FR07C0073C patent/FR07C0073I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91400I2 (fr) | "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard | |
DE122008000010I1 (de) | Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine |